Thematics Asset Management Has $28.83 Million Holdings in Hologic, Inc. $HOLX

Key Points

• Thematics Asset Management has reduced its holdings in Hologic, Inc. by 10.6% during the first quarter, selling 55,317 shares, and now holds approximately 466,744 shares, making it the 15th largest position in their portfolio.
• In the first quarter, several hedge funds made strategic changes to their positions in Hologic, with Larson Financial Group LLC increasing its stake by 6,016.7%, bringing their total to 734 shares.
• Analyst ratings for Hologic stock show an average rating of "Moderate Buy" with a target price of $78.00, while recent earnings showed a slight increase in revenue year-over-year.

Thematics Asset Management trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 10.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 466,744 shares of the medical equipment provider's stock after selling 55,317 shares during the period. Hologic accounts for approximately 1.5% of Thematics Asset Management's holdings, making the stock its 15th largest position. Thematics Asset Management owned about 0.21% of Hologic worth $28,831,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Victory Capital Management Inc. raised its stake in shares of Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after buying an additional 1,692,177 shares in the last quarter. Invesco Ltd. boosted its stake in Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock worth $298,655,000 after acquiring an additional 764,573 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Hologic by 1.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider's stock worth $276,303,000 after buying an additional 69,878 shares during the period. Ameriprise Financial Inc. raised its holdings in shares of Hologic by 0.8% in the first quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider's stock valued at $216,973,000 after purchasing an additional 29,133 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Hologic by 26.9% in the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after purchasing an additional 668,086 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on HOLX shares. Stephens lowered their target price on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. UBS Group upped their price target on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research note on Thursday, July 31st. Wall Street Zen upgraded shares of Hologic from a "hold" rating to a "buy" rating in a research note on Friday. Evercore ISI upped their price target on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Finally, Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their price objective for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, Hologic currently has a consensus rating of "Moderate Buy" and an average target price of $78.00.

Hologic Price Performance

Shares of HOLX stock traded down $0.50 on Tuesday, reaching $66.63. The company had a trading volume of 3,038,660 shares, compared to its average volume of 1,841,128. The stock has a market capitalization of $14.82 billion, a PE ratio of 27.65, a price-to-earnings-growth ratio of 2.44 and a beta of 0.49. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.39. The business's 50-day moving average is $65.99 and its 200 day moving average is $62.45.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the business earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.